Healthcare providers can now upload data from a Tandem pump and blood glucose meter simultaneously, according to Tandem. They can also find patients quickly and set patient-specific ranges to identify data that fall outside of goals.
The original t:connect app was designed with patient-input, Tandem said, and enables patients to monitor diabetes goals in-between clinic visits. The company reported that more than half of Tandem pump users have logged into the t:connect app in the last 90 days and upload 3 times per month on average.
The t:connect HCP Portal was developed on feedback from physicians, nurses and diabetes educators to streamline their use of the original t:connect app.
In March, Tandem announced the pricing details of a $22.5 million underwritten public offering. The company priced 18 million shares of its common stock at $1.25 apiece.
Tandem also gave underwriters a 30-day option to buy up to an additional 2.7 million shares of common stock at the public offering price. The offering is expected to close on March 28.
Earlier that month, the medical device maker met expectations on Wall Street with its 4th quarter results.
The San Diego-based company posted losses of -$15.7 million, or -48¢ per share, on sales of $24.8 million for the 3 months ended Dec. 31, for bottom-line loss of -40% on sales loss of -15% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were -48¢, ahead of consensus on The Street, where analysts were looking for sales of $22.8 million.